Internal Reference Number: FOI_7253
Date Request Received: 20/06/2023 00:00:00
Date Request Replied To: 28/06/2023 00:00:00
This response was sent via: By Email
Request Summary: Breast Cancer
Request Category: Companies
| Question Number 1: How many patients have been treated for breast cancer (any stage) in the past 3 months with the following systemic anti-cancer therapies: • Abemaciclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) • Abemaciclib + Fulvestrant • Alpelisib + Fulvestrant • Anthracycline (e.g. doxorubicin or epirubicin) as a single agent • Atezolizumab +Nab-paclitaxel/Paclitaxel • Capecitabine as a single agent • Eribulin as a single agent or in combination • Everolimus + Exemestane • Fulvestrant as a single agent • Lapatinib • Neratinib • Parp Inhibitors (Olaparib/Talazoparib) • Palbociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) • Palbociclib + Fulvestrant • Pembrolizumab • Platinum (e.g. carboplatin or cisplatin) as a single agent • Ribociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) • Ribociclib + Fulvestrant • Sacituzumab Govitecan • Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent • Taxane and/or Anthracycline in combination • Trastuzumab as a single agent or in combination • Trastuzumab emtansine • Transtuzumab deruxtecan • Any other active systemic anti-cancer therapy | |
| Answer To Question 1: • Abemaciclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) <5 • Abemaciclib + Fulvestrant 7 • Alpelisib + Fulvestrant 0 • Anthracycline (e.g. doxorubicin or epirubicin) as a single agent 0 • Atezolizumab +Nab-paclitaxel/Paclitaxel 5 • Capecitabine as a single agent 6 • Eribulin as a single agent or in combination <5 • Everolimus + Exemestane <5 • Fulvestrant as a single agent <5 • Lapatinib 0 • Neratinib 0 • Parp Inhibitors (Olaparib/Talazoparib) 0 • Palbociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) 35 • Palbociclib + Fulvestrant 7 • Pembrolizumab <5 • Platinum (e.g. carboplatin or cisplatin) as a single agent 0 • Ribociclib + Aromatase Inhibitor (e.g. anastrazole, exemestane, letrozole) <5 • Ribociclib + Fulvestrant 0 • Sacituzumab Govitecan <5 • Taxane (e.g. docetaxel, paclitaxel, nab-paclitaxel) as a single agent 7 • Taxane and/or Anthracycline in combination 16 • Trastuzumab as a single agent or in combination 44 • Trastuzumab emtansine <5 • Transtuzumab deruxtecan <5 • Any other active systemic anti-cancer therapy 0 | |
| Question Number 2: Does your trust participate in any clinical trials for the treatment of breast cancer? If so, please provide the name of each trial and the number of patients taking part. | |
| Answer To Question 2: Yes: Cando-3 36 participants OPTIMA 43 participants | |
| To return to the list of all the FOI requests please click here |
Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of ¿´Æ¬Èí¼þ Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
